Title: Full Text of HB2346
Official Title: 
Number of Sections: 1
Source: versions - Introduced
Media Type: text/html

================================================================================

Section 1:
Full Text of HB2346 ILGA.GOV HB2346 - 104th General Assembly 104TH GENERAL ASSEMBLY State of Illinois 2025 and 2026HB2346 Introduced 2/4/2025, by Rep. Laura Faver Dias SYNOPSIS AS INTRODUCED: 410 ILCS 715/5410 ILCS 715/45410 ILCS 715/55410 ILCS 715/70 new    Amends the Illinois Drug Reuse Opportunity Program Act. Requires the Illinois Department of Public Health: (1) to develop, maintain, and publish on its website information regarding the names and locations of pharmacies participating in the program; (2) to educate pharmacies in the State about the program and how to participate in it voluntarily; (3) to develop and publish educational materials to allow program participants and the Department to inform the general public about the purposes and benefits of the program; and (4) to collect information from participants and publish the information in an annual report to the General Assembly by December 31 of each calendar year, beginning December 31, 2026. Specifies that records maintained under the Act are subject to access by the Department upon request. Defines "Department".LRB104 06540 BDA 16576 b  A BILL FOR HB2346LRB104 06540 BDA 16576 b1    AN ACT concerning health. 2    Be it enacted by the People of the State of Illinois, 3represented in the General Assembly: 4    Section 5. The Illinois Drug Reuse Opportunity Program Act 5is amended by changing Sections 5, 45, 55, and 70 as follows: 6    (410 ILCS 715/5)7    Sec. 5. Definitions. In this Act:8    "Controlled substance" means a drug, substance, or 9immediate precursor in Schedules I through V of 21 CFR 1308.10    "Department" means the Illinois Department of Public 11Health. 12    "Dispense" has the same meaning as defined in Section 3 of 13the Pharmacy Practice Act.14    "Donor" means any person, including an individual member 15of the public, or any entity legally authorized to possess 16medicine, including, but not limited to, a wholesaler or 17distributor, third party logistic provider, pharmacy, 18dispenser, clinic, surgical or health center, detention and 19rehabilitation center, jail, prison laboratory, medical or 20pharmacy school, prescriber or other health care professional, 21long-term care facility, or healthcare facility. "Donor" 22includes government agencies and entities that are federally 23authorized to possess medicine, including, but not limited to,   HB2346- 2 -LRB104 06540 BDA 16576 b1drug manufacturers, repackagers, relabelers, outsourcing 2facilities, health care facilities operated by the U.S. 3Department of Veterans Affairs, and prisons.4    "Drug" means a prescription drug, over-the-counter drug, 5or supplies needed to administer a prescription or 6over-the-counter drug.7    "Eligible patient" means an individual:8        (1) with a prescription for the drug, if a 9    prescription is required to dispense the drug, or who 10    reports symptoms treated by the drug if the drug is 11    over-the-counter; and12        (2) who is registered with the drug's manufacturer in 13    accordance with federal Food and Drug Administration 14    requirements, if the registration is required to dispense 15    the drug.16    "Manufacturer" has the same meaning as defined in Section 1715 of the Wholesale Drug Distribution Licensing Act.18    "Pharmacist" means an individual licensed to engage in the 19practice of pharmacy under the Pharmacy Practice Act or 20licensed to engage in the practice of pharmacy in another 21state.22    "Practitioner" means a person licensed in this State to 23dispense or administer drugs or who is licensed in another 24state as a person authorized to dispense or administer drugs.25    "Prescription drug" means any prescribed drug that may be 26legally dispensed by a pharmacy. "Prescription drug" does not   HB2346- 3 -LRB104 06540 BDA 16576 b1include a drug for the treatment of cancer that can only be 2dispensed to a patient registered with the drug manufacturer 3in accordance with the federal Food and Drug Administration's 4requirements.5    "Priority patient" means an eligible patient who is an 6Illinois resident and who is indigent, uninsured, 7underinsured, or enrolled in a public health benefits program.8    "Recipient" means any person or entity legally authorized 9to possess medicine with a license or permit in the state in 10which the person or entity is located, including, but not 11limited to, a wholesaler or distributor, reverse distributor, 12repackager, hospital, pharmacy, or clinic.13    "Returns processor" has the same meaning as defined in 14paragraph (18) of 21 U.S.C. 360eee. "Returns processor" 15includes, but is not limited to, a reverse distributor.16    "Unopened tamper-evident packaging" has the same meaning 17as defined in the United States Pharmacopeia (USP) General 18Chapter 659, Packaging and Storage Requirements, including, 19but not limited to, unopened unit-dose, multiple-dose, 20immediate, secondary, and tertiary packaging.21(Source: P.A. 102-389, eff. 1-1-22.) 22    (410 ILCS 715/45)23    Sec. 45. Recordkeeping requirements. When performing any 24action associated with a program under this Act or otherwise 25processing a donated drug for tax, manufacturer, or other   HB2346- 4 -LRB104 06540 BDA 16576 b1credit, a recipient shall be considered to be acting as a 2returns processor and shall comply with all recordkeeping 3requirements for nonsalable nonsaleable returns under federal 4law. Records maintained under this Act may be accessed by the 5Department upon request. 6(Source: P.A. 102-389, eff. 1-1-22.) 7    (410 ILCS 715/55)8    Sec. 55. Retention of records. All records required under 9this Act shall be retained in physical or electronic format 10and on or off the recipient's premises for a period of 6 years. 11Donors or recipients may contract with one another or a third 12party to create or maintain records on each other's behalf. An 13identifier, such as a serial number or bar code, may be used in 14place of any or all information required by a record or label 15pursuant to this Act if it allows for such information to be 16readily retrievable. Upon request by a State or federal 17regulatory agency, the identifier used for requested records 18shall be replaced with the original information. An identifier 19shall not be used on patient labels when dispensing or 20administering a drug. Records maintained under this Act may be 21accessed by the Department upon request. 22(Source: P.A. 102-389, eff. 1-1-22.) 23    (410 ILCS 715/70 new)24    Sec. 70. Program support provided by the Department. The   HB2346- 5 -LRB104 06540 BDA 16576 b1Department shall:2        (1) develop, maintain, and publish on its website 3    information regarding the names and locations of 4    pharmacies participating in the program;5        (2) educate pharmacies in the State about the program 6    and how to participate in it voluntarily;7        (3) develop and publish educational materials to allow 8    program participants and the Department to inform the 9    general public about the purposes and benefits of the 10    program; and11        (4) collect information from participants and publish 12    the information in an annual report to the General 13    Assembly by December 31 of each calendar year, beginning 14    December 31, 2026.


================================================================================

Raw Text:
Full Text of HB2346 ILGA.GOV HB2346 - 104th General Assembly 104TH GENERAL ASSEMBLY State of Illinois 2025 and 2026HB2346 Introduced 2/4/2025, by Rep. Laura Faver Dias SYNOPSIS AS INTRODUCED: 410 ILCS 715/5410 ILCS 715/45410 ILCS 715/55410 ILCS 715/70 new    Amends the Illinois Drug Reuse Opportunity Program Act. Requires the Illinois Department of Public Health: (1) to develop, maintain, and publish on its website information regarding the names and locations of pharmacies participating in the program; (2) to educate pharmacies in the State about the program and how to participate in it voluntarily; (3) to develop and publish educational materials to allow program participants and the Department to inform the general public about the purposes and benefits of the program; and (4) to collect information from participants and publish the information in an annual report to the General Assembly by December 31 of each calendar year, beginning December 31, 2026. Specifies that records maintained under the Act are subject to access by the Department upon request. Defines "Department".LRB104 06540 BDA 16576 b  A BILL FOR HB2346LRB104 06540 BDA 16576 b1    AN ACT concerning health. 2    Be it enacted by the People of the State of Illinois, 3represented in the General Assembly: 4    Section 5. The Illinois Drug Reuse Opportunity Program Act 5is amended by changing Sections 5, 45, 55, and 70 as follows: 6    (410 ILCS 715/5)7    Sec. 5. Definitions. In this Act:8    "Controlled substance" means a drug, substance, or 9immediate precursor in Schedules I through V of 21 CFR 1308.10    "Department" means the Illinois Department of Public 11Health. 12    "Dispense" has the same meaning as defined in Section 3 of 13the Pharmacy Practice Act.14    "Donor" means any person, including an individual member 15of the public, or any entity legally authorized to possess 16medicine, including, but not limited to, a wholesaler or 17distributor, third party logistic provider, pharmacy, 18dispenser, clinic, surgical or health center, detention and 19rehabilitation center, jail, prison laboratory, medical or 20pharmacy school, prescriber or other health care professional, 21long-term care facility, or healthcare facility. "Donor" 22includes government agencies and entities that are federally 23authorized to possess medicine, including, but not limited to,   HB2346- 2 -LRB104 06540 BDA 16576 b1drug manufacturers, repackagers, relabelers, outsourcing 2facilities, health care facilities operated by the U.S. 3Department of Veterans Affairs, and prisons.4    "Drug" means a prescription drug, over-the-counter drug, 5or supplies needed to administer a prescription or 6over-the-counter drug.7    "Eligible patient" means an individual:8        (1) with a prescription for the drug, if a 9    prescription is required to dispense the drug, or who 10    reports symptoms treated by the drug if the drug is 11    over-the-counter; and12        (2) who is registered with the drug's manufacturer in 13    accordance with federal Food and Drug Administration 14    requirements, if the registration is required to dispense 15    the drug.16    "Manufacturer" has the same meaning as defined in Section 1715 of the Wholesale Drug Distribution Licensing Act.18    "Pharmacist" means an individual licensed to engage in the 19practice of pharmacy under the Pharmacy Practice Act or 20licensed to engage in the practice of pharmacy in another 21state.22    "Practitioner" means a person licensed in this State to 23dispense or administer drugs or who is licensed in another 24state as a person authorized to dispense or administer drugs.25    "Prescription drug" means any prescribed drug that may be 26legally dispensed by a pharmacy. "Prescription drug" does not   HB2346- 3 -LRB104 06540 BDA 16576 b1include a drug for the treatment of cancer that can only be 2dispensed to a patient registered with the drug manufacturer 3in accordance with the federal Food and Drug Administration's 4requirements.5    "Priority patient" means an eligible patient who is an 6Illinois resident and who is indigent, uninsured, 7underinsured, or enrolled in a public health benefits program.8    "Recipient" means any person or entity legally authorized 9to possess medicine with a license or permit in the state in 10which the person or entity is located, including, but not 11limited to, a wholesaler or distributor, reverse distributor, 12repackager, hospital, pharmacy, or clinic.13    "Returns processor" has the same meaning as defined in 14paragraph (18) of 21 U.S.C. 360eee. "Returns processor" 15includes, but is not limited to, a reverse distributor.16    "Unopened tamper-evident packaging" has the same meaning 17as defined in the United States Pharmacopeia (USP) General 18Chapter 659, Packaging and Storage Requirements, including, 19but not limited to, unopened unit-dose, multiple-dose, 20immediate, secondary, and tertiary packaging.21(Source: P.A. 102-389, eff. 1-1-22.) 22    (410 ILCS 715/45)23    Sec. 45. Recordkeeping requirements. When performing any 24action associated with a program under this Act or otherwise 25processing a donated drug for tax, manufacturer, or other   HB2346- 4 -LRB104 06540 BDA 16576 b1credit, a recipient shall be considered to be acting as a 2returns processor and shall comply with all recordkeeping 3requirements for nonsalable nonsaleable returns under federal 4law. Records maintained under this Act may be accessed by the 5Department upon request. 6(Source: P.A. 102-389, eff. 1-1-22.) 7    (410 ILCS 715/55)8    Sec. 55. Retention of records. All records required under 9this Act shall be retained in physical or electronic format 10and on or off the recipient's premises for a period of 6 years. 11Donors or recipients may contract with one another or a third 12party to create or maintain records on each other's behalf. An 13identifier, such as a serial number or bar code, may be used in 14place of any or all information required by a record or label 15pursuant to this Act if it allows for such information to be 16readily retrievable. Upon request by a State or federal 17regulatory agency, the identifier used for requested records 18shall be replaced with the original information. An identifier 19shall not be used on patient labels when dispensing or 20administering a drug. Records maintained under this Act may be 21accessed by the Department upon request. 22(Source: P.A. 102-389, eff. 1-1-22.) 23    (410 ILCS 715/70 new)24    Sec. 70. Program support provided by the Department. The   HB2346- 5 -LRB104 06540 BDA 16576 b1Department shall:2        (1) develop, maintain, and publish on its website 3    information regarding the names and locations of 4    pharmacies participating in the program;5        (2) educate pharmacies in the State about the program 6    and how to participate in it voluntarily;7        (3) develop and publish educational materials to allow 8    program participants and the Department to inform the 9    general public about the purposes and benefits of the 10    program; and11        (4) collect information from participants and publish 12    the information in an annual report to the General 13    Assembly by December 31 of each calendar year, beginning 14    December 31, 2026.